Related Experiment Video

Updated: Oct 18, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

Vorinostat (SAHA) and Breast Cancer: An Overview

Anna Wawruszak1, Lidia Borkiewicz1, Estera Okon1

  • 1Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland.

Cancers
|September 28, 2021
PubMed

Insights

Vorinostat (SAHA), a histone deacetylase inhibitor, shows promise in treating breast carcinoma (BC) by inhibiting cancer cell proliferation. This review analyzes SAHA

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Histone deacetylase inhibitors (HDIs) are emerging anticancer agents.
  • Vorinostat (SAHA) is the first approved HDI for cutaneous T-cell lymphoma.
  • Breast carcinoma (BC) presents therapeutic challenges due to heterogeneity, toxicity, and drug resistance.

Purpose of the Study:

  • To analyze preclinical and clinical data on Vorinostat (SAHA) for breast carcinoma treatment.
  • To evaluate SAHA's efficacy as a single agent and in combination therapies.
  • To consider the impact of different BC histological subtypes on SAHA's effectiveness.

Main Methods:

  • Systematic review of preclinical studies.
  • Analysis of clinical trial data.
  • Evaluation of SAHA in various breast carcinoma models and patient cohorts.

Main Results:

  • SAHA demonstrates antiproliferative effects across various cancer cell types, including breast carcinoma.
  • Combination therapies involving SAHA show potential for enhanced efficacy.
  • Response to SAHA may vary depending on the specific histological subtype of breast carcinoma.

Conclusions:

  • Vorinostat (SAHA) is a promising agent for breast carcinoma treatment, warranting further investigation.
  • Combination strategies with SAHA could overcome resistance and reduce toxicity.
  • Tailoring SAHA-based therapy to BC subtypes may improve patient outcomes.
Keywords:
breast cancerepigeneticshistone acetylationhistone deacetylase inhibitor (HDI)histone deacetylases (HDACs)suberoylanilide hydroxamic acidtargeted therapyvorinostat (SAHA)

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.5K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.4K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
568